<DOC>
	<DOCNO>NCT00242333</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety tolerability AD 237 patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Different AD 237 Doses Adults With COPD</brief_title>
	<detailed_description />
	<criteria>Diagnosed COPD , symptom cough chronic sputum production and/or dyspnea . Postbronchodilator FEV1 65 % least 30 % predict normal value . Prebronchodilator FEV1/FVC ratio le 70 % . Current exsmokers smoke history least 10 pack year . History asthma , atopy allergic rhinitis . Other serious respiratory medical condition may interfere outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>COPD</keyword>
	<keyword>COAD</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>emphysema</keyword>
	<keyword>chronic bronchitis</keyword>
</DOC>